Autoresearch: PBM pass-through pre-emption and where the spread profit pool actually goes

Generated by /autoresearch on 2026-07-17. Synthesized across 3 rounds from 11 web pages (6 fetch failures), anchored by the Grokipedia "Pharmacy benefit management" entry. See Provenance. Treat as raw material — review before promoting into a project or thread. Context: vault/projects/stock-market — researched as the gap against drug-pricing-reform-pbm-spread-compression, which already covers the 2026 policy stack (OPPS acquisition-cost survey, CAA 2026 Part-D fee de-linking, FTC insulin action, 340B, MFN/TrumpRx) and the CVS/CI/UNH + AMZN framing. This pass deliberately does not re-litigate those. Headless run — priors capture skipped (no user available). No Priors check section; the "Calibration flag" below is the equivalent output against the existing hypothesis page's stated chain rather than against a human's stated beliefs.

Summary

The load-bearing finding inverts the existing hypothesis page. Optum's 2026-07-16 commitment to move ~95% of PBM clients to 100% pass-through by end-2026 is not an incumbent conceding a profit pool — it is cheap pre-emption of a pool it already left. PBM revenue composition moved decisively between 2012 and 2023: rebates and related cash streams fell from ~50% of revenue to under 15%, while specialty pharmacy rose 16%→35% and administrative fees 5%→22% (Forbes / Joshua Cohen, 2026-06-01). A 100% pass-through promise on rebates is therefore a promise about the smallest and fastest-shrinking of the three pools.

Round 2 surfaced the proximate trigger the earnings call didn't state: the FTC's insulin case against all three PBM-GPO pairs resolved or near-resolved in the weeks before the call — Caremark settled (FTC press release dated 2026/07, fetch-blocked; see Contradictions on dates), Optum Rx "accepted a proposed settlement in June 2026" with terms undisclosed, and the 8th Circuit dismissed the PBMs' countersuit against the FTC on 2026-07-01 (Healthcare Dive).

Round 3 found the hedge, and it is explicit rather than inferred. Drug Channels lists "hedge against future PBM regulation" as a standing reason the big PBMs built GPOs at all, on the reasoning that reforms target rebates and spread while "there is no parallel effort to alter GPO safe harbor rules" (Drug Channels). Manufacturers paid an estimated $7.6 billion in fees to the rebate aggregators in 2022 alone (Frier Levitt / search synthesis). The counter-fact that keeps this honest: the CAA 2026 does name the workaround — it requires remittance of 100% of "rebates, fees, alternative discounts, and other remuneration received from manufacturers, GPOs, and rebate aggregators" — but not until 2028-2029 (Mintz). The hedge has a shelf life; it is a 2028 problem, not a 2026 one.

Calibration flag (against the existing hypothesis page)

The existing page frames "the spread-dependent PBM-insurers (CVS, CI, UNH) are the risk/avoid side if compression bites." This research contradicts the premise, not the arithmetic: compression is real and arriving, but the spread is no longer where the profit is, so compression bites a pool that is already <15% of PBM revenue and shrinking. Steps 2–3 of that page (flagged there as ⚠ unverified — magnitude not yet sized) now have evidence pointing the other direction. Worth a /calibrate entry if the page's chain is retained. The page's step 4 (AMZN/transparent-channel beneficiary) is untouched by this pass.

Findings

1. The pass-through commitments are an industry-wide, multi-year, voluntary sequence — not a UNH-specific event

Optum is the last mover, not the first. The sequence, oldest to newest:

• Express Scripts (CI) announced ClearNetwork in November 2023 — a flat pharmacy fee plus a 15% fee across 65,000 retail pharmacies (PharmExec).
• CVS (Caremark) announced CostVantage (retail reimbursement) and TrueCost (PBM), with cash discount cards in H1 2024, PBM launches in 2025 (PharmExec). CVS's earlier Guaranteed Net Cost model already passed through "100 percent of rebates to plan sponsors." By 2025, clients representing more than 75% of CVS Caremark commercial lives had chosen to implement two or more elements of the new model (search synthesis over Fierce Healthcare / CVS materials — page 403'd; figure is from the search layer, see Contradictions).
• OptumRx (UNH) introduced Cost Clarity, reimbursing pharmacies at a logic approaching acquisition cost (NADAC or WAC) plus a defined markup plus a dispensing fee, "with full implementation targeted by 2028" (search synthesis) — against which the 2026-07-16 call's "95% of clients on 100% pass-through by end of 2026" is an acceleration.

The motive is stated on the record by a former regulator, not inferred: Scott Gottlieb, on CVS's move, said that "as congress is set to act on rebates, then the benefits of paying pharmacies based on complex contracts...is starting to diminish" (PharmExec). PharmExec's own framing: this implies voluntary preemption ahead of anticipated congressional action, with no explicit regulatory mandate at the time.

"Who is forced to follow" is the wrong question. CVS and Cigna moved first (2023), UNH moved last (2026). Nobody is being forced to follow Optum.

2. Pass-through relocates PBM profit; it does not eliminate it

Two independent mechanisms, both cited:

(a) Cost-plus formulas hide the margin in the inputs. CVS CostVantage reimburses on three components: an acquisition cost index ("internally-computed," organized into unspecified "buckets"), an undisclosed percentage markup negotiated individually per payer, and a flat dispensing fee. Drug Channels' verdict is direct: cost-plus "shift[s] compensation for prescriptions from a spread-based model to a service-based model," but "PBM profits relocate rather than disappear" — CVS's vertical integration means that through subsidiary Cordavis it "could use its other businesses to establish acquisition cost benchmarks that enable higher reimbursement to its pharmacies." Plan sponsors face the same old problem: because markups are negotiated per payer, "different payers and plans will pay different amounts for the same prescription — replicating current problems rather than solving them," and clients get only "some sort of audit rights" rather than genuine oversight (Drug Channels).

(b) The GPO layer converts a regulated rebate into an unregulated fee. Ascent Health Services (Cigna/Evernorth, formed 2019, Switzerland), Zinc Health Services (CVS Health, 2020, Minnesota), and Emisar Pharma Services (UnitedHealth/Optum, 2021, Ireland) sit between the PBMs and manufacturers (Grokipedia: Ascent, Zinc and Emisar; Drug Channels). Drug Channels' five reasons include, explicitly: new revenue streams from manufacturers ("contracting entity administrative fees, prescription data services, data portals, enterprise fees," supplementing typical PBM admin fees of "3% to 5% of the WAC list price value"); reduced transparency and pass-through obligations (GPO "businesses and finances are less transparent to plan sponsors," so "a smaller share of those revenues are passed through"); tax efficiencies (Switzerland/Ireland "transfer pricing and rebate accounting using other countries' lower corporate tax rates"); and the regulatory hedge quoted in the Summary.

The mechanic, stated by the search layer over the Buchanan Ingersoll piece (page 403'd — see Contradictions): "If what used to be a rebate is reclassified as a GPO 'administrative fee,' the money moves to a different bucket — one clients can't claim and regulators haven't regulated, and one that sits offshore." Economic substance of rebate retention "can remain intact even as contractual promises appear satisfied" (Buchanan Ingersoll & Rooney, via search synthesis).

Enforcement precedent that the retention is real, not theoretical: in 2024 the Illinois Attorney General recovered $45 million from CVS Caremark for retaining rebate funds associated with Zinc that should have been passed to clients (Grokipedia). A federal judge in Rhode Island declined to dismiss that state's suit against all three PBMs (Frier Levitt, via search synthesis).

The shelf life. The CAA 2026's commercial-market provision reaches GPO money by name — 100% remittance of remuneration from "manufacturers, GPOs, and rebate aggregators," quarterly within 90 days, GPO/aggregator pass-through within 45 days, auditable by a plan-selected auditor the PBM cannot fund. Part D goes further with a bona fide service fee model: compensation "only in the form of a bona fide service fee" — flat, fair-market-value, for a service actually performed, and which "does not vary based on drug price, Rebates, coverage or formulary decisions." Effective 2028 plan year (Part D) and 2028-2029 (commercial). Medicaid is explicitly excluded (GAO study only). Mintz flags the live ambiguity: "The statute does not carve out PBM-affiliated entities; however, it remains unclear whether affiliated GPOs trigger separate compliance obligations. The text does not explicitly address this gap." (Mintz).

3. The binding-now forcing function is state NADAC floors, not federal law

The federal statute bites in 2028. State laws bite now, and they set a hard cash floor under pharmacy reimbursement in the commercial market — which is where PBM spread lived. From Frier Levitt's 2026 state PBM reform survey unless noted:

Frier Levitt's own read on incidence: the increased costs "are borne primarily by PBMs and health plans, reducing PBM profit margins and requiring plan sponsors to adjust pricing structures."

Why this is the sharper forcing function: these are dated, in-force, dollar-denominated, and they bind the commercial book two-to-three years before the CAA does. New Jersey's A. 1502 in particular pairs a NADAC floor with PBM fiduciary duty and an anti-affiliate-preference rule — i.e. it attacks the CostVantage relocation route (§2a) and the Cordavis benchmark route simultaneously.

4. The beneficiary side: independent pharmacies (private) → the wholesalers that serve them (MCK, COR, CAH)

The mechanism by which pharmacies were being squeezed is quantified. Wholesalers price brand drugs to large chains at roughly 94% of WAC (a 6% sell-side discount) but cut GLP-1 discounts for smaller pharmacies to only 98% of WAC (2%); meanwhile "PBMs' reimbursements to pharmacies typically average 96% of WAC or lower" — so many independents dispense below acquisition cost despite high volume (Drug Channels). The NADAC-plus-dispensing-fee floor is precisely a legal prohibition on that gap.

The damage to date: PBM reimbursement spreads that "squeeze independent pharmacies' margins" contributed to over 1,200 closures since 2013, particularly rural (Grokipedia: Pharmacy benefit management); NCPA reports "thousands of pharmacies shuttered their doors in 2024 and 2025," which is what "prompt[ed] state policymakers to accelerate legislation" (NCPA, via search synthesis).

The listed exposure to that channel:

• MCK — Health Mart: "nearly 4,000 high-performing, locally owned independent community pharmacies" (McKesson).
• COR (Cencora) — Good Neighbor Pharmacy: "more than 4,000 community pharmacy owners" as of July 2025 (Cencora).
• CAH — no independent-franchise figure surfaced in this pass.

Note the sign of the margin asymmetry: wholesalers earn their thinnest sell-side discounts — i.e. their best margin — on small pharmacies, and receive the "lowest buy-side distribution fees (as a share of cost) for brand-name products sold by the largest manufacturers," which compresses margin when serving major chains (Drug Channels). An independent-pharmacy channel that stops shrinking is therefore worth disproportionately more to MCK/COR than the raw script count implies. This is the chain's inferential leap — see Contradictions.

Counter-evidence, recorded honestly. The wholesalers' own stated growth strategy points away from retail distribution: the Big Three have spent over $16 billion since 2013 acquiring or partnering with physician-practice MSOs, because traditional distribution is thin-margin ("buy low, sell high, collect early, pay late") and clinical services are "higher-margin... stabilizing profits and reducing dependency on distribution spreads" (Drug Channels). Separately, both franchise networks are losing Part D preferred status: McKesson's Health Mart Atlas participates directly in only two HCSC plans with members otherwise non-preferred, and Cencora's Elevate members "will not be preferred in any major plan for 2026" — a ninth consecutive year (Drug Channels). Independents are walking away from Part D networks at the same time state law is improving their commercial economics.

5. The real tail risk to CVS/CI/UNH is divestiture of the new pool, not compression of the old one

The Patients Before Monopolies Act (bipartisan, reintroduced ~May 2026) would require PBM-owning conglomerates to divest retail pharmacies within one year if enacted; Forbes notes "no guarantee that such a law will pass" (Forbes). The bite: it would force divestiture of specialty pharmacy — the pool that grew 16%→35% of PBM revenue and which Forbes characterizes as "one of the industry's major profit engines." Arkansas HB 1150 is the state-level version, enjoined since 2025-07-28.

So the structural risk to CVS/CI/UNH is real but mispriced by mechanism: it lives in ownership/divestiture law aimed at specialty pharmacy, not in spread transparency. Low probability, high impact, no dated catalyst — a watch item, not a chain.

Candidate causal chains (for the project's chain test)

Chain A — "Pass-through is cheap; the derate premise is wrong." (strongest; contradicts an existing page) FTC insulin consents (Caremark settled 2026; Optum accepted proposed settlement June 2026; 8th Cir. dismissed PBM countersuit 2026-07-01) + CAA 2026 signed Feb 2026 → all three PBMs pre-commit to 100% rebate pass-through ahead of a 2028-29 effective date → but rebates are already <15% of PBM revenue (from ~50% in 2012) while specialty (35%) + admin fees (22%) carry the P&L, and GPO fees ($7.6B/2022) sit offshore under untouched safe-harbor rules that Drug Channels names as a deliberate regulatory hedge → the spread-compression bear case on CVS / CI / UNH does not clear the bar through 2027. Tradeable: neutral-to-constructive CVS/CI/UNH on this mechanism specifically; the existing page's avoid-side is unsupported. Falsifier: CAA 2028 arrival, or a rule reaching affiliated GPOs early. Every link cited; the inference that FTC consents caused the 07-16 announcement is mine (see below).

Chain B — "State NADAC floors reflate the independent channel." (real forcing function, weak final link) State laws mandating NADAC + $10.05–$15 dispensing fees in the commercial market (CA Oct 2025; KY 2025; CT/MT/IN Jan 1 2026; NJ passed Assembly 2026-05-21) → PBMs legally cannot reimburse below acquisition cost, killing the 96%-of-WAC-vs-98%-acquisition squeeze → independent pharmacy closures (1,200+ since 2013) decelerate → the franchise channels stabilize: MCK (Health Mart, ~4,000) and COR (Good Neighbor, 4,000+), where wholesaler sell-side margin is structurally better than on chains → MCK / COR benefit. ⚠ The final link is unevidenced (below), and §4's counter-evidence cuts against it.

Chain C — "The breakup bill targets specialty, not spread." (watch item, not yet a chain) Patients Before Monopolies Act + Arkansas HB 1150 (enjoined) → divestiture of PBM-owned pharmacies → strands specialty pharmacy, 35% of PBM revenue → CVS / UNH / CI structural derate. No dated catalyst, passage uncertain. Not tradeable today; worth arming.

Contradictions and open questions

Unevidenced links — flagged, not smoothed over:

• Chain B's terminal link is my inference, not a sourced claim. No source in this pass quantifies wholesaler earnings sensitivity to independent-pharmacy count, and no MCK/COR/CAH management commentary from the past 30 days surfaced connecting state NADAC floors to their outlook. The margin asymmetry (94% vs 98% of WAC) and the franchise-count figures are cited, but combining them into "independent survival is worth disproportionately more to MCK/COR" is an unverified synthesis step. §4's counter-evidence ($16B MSO pivot away from distribution; nine straight years of Elevate non-preferred status) actively cuts against it. Do not emit a signal on Chain B without sizing this.
• The FTC-consent → 07-16-announcement causal link is my inference. No source states that Optum's proposed FTC settlement (June 2026) caused or shaped the "95% by end-2026" commitment. The timing is suggestive; the mechanism is not sourced. Optum's settlement terms are undisclosed, so it is possible the consent agreement requires the pass-through — which would flip the finding from "voluntary pre-emption" to "mandated," and would materially change Chain A. This is the single highest-value thing to resolve.
• The 2012→2023 revenue-mix figures (50%→15% / 16%→35% / 5%→22%) carry Chain A and appear in two places (Forbes and a search synthesis over the same underlying material), but I could not trace them to the primary study. Effectively single-sourced; they are also 2023 data being used to argue about 2026.
• The $7.6B GPO fee figure (2022) comes from the search layer over Frier Levitt, not from a fetched page — the primary was not retrieved.

Source conflicts on the FTC settlement timeline (unresolved):

• Healthcare Dive says Express Scripts finalized February 2025 and Caremark agreed to a proposed settlement in March 2026 with "specific terms remain unpublished."
• The search layer says Express Scripts settled February 2026 ("projected up to $7 billion," "reshoring Ascent from Switzerland") and Caremark's settlement is a July 2026 FTC announcement ("up to $8.5 billion in consumer savings over the next decade").
• The FTC's own press-release URL is dated 2026/07.
• ftc.gov 403'd on three separate attempts, so I could not verify against the primary. The Ascent-reshoring claim in particular would be materially important (it would partially close the offshore leg of Chain A) and is snippet-only — treat as unverified.

Open questions:

• Do Optum's and Caremark's FTC consent orders reach the affiliated GPOs (Emisar, Zinc), or only rebate practices? This determines whether Chain A's hedge survives to 2028.
• Does any PBM disclose GPO fee revenue separately? Without it, "100% pass-through" is unauditable from outside, and the Mintz-flagged ambiguity ("unclear whether affiliated GPOs trigger separate compliance obligations") stays live.
• Is there a listed pure-play transparent PBM or independent-pharmacy expression? This pass found none — Navitus, Capital Rx, AffirmedRx, Cost Plus are private; Walgreens is no longer listed; Rite Aid is gone. The beneficiary side of the existing hypothesis page may simply have no clean ticker, which is itself a finding.
• What share of CVS/CI/UNH EBIT is GPO-routed? Still unsized — the same gap the existing page flagged in June, now sharper because we know which pool to size.

Provenance

Rounds run: 3 (full). Note: run headless — §0 interactive priors capture skipped per instruction. --fanout was requested but the Workflow tool is unavailable in this context, so the canonical sequential route was run instead (identical output contract).

Sub-questions by round:

Round 1 (broad survey):

1. Have CVS/Caremark and Cigna/Express Scripts committed to pass-through/cost-plus models, and on what timeline?
2. What replaces the spread as the PBM profit pool?
3. Do wholesaler (MCK/COR/CAH) economics change when reimbursement moves to acquisition-cost-plus?
4. What does 2026 regulation actually require vs. what is being pre-empted voluntarily?

Round 2 (drill-down):

1. What is the actual status and content of the FTC insulin consents? — targeting the trigger for the 07-16 announcement
2. What do 2026 state PBM laws mandate, in which markets, effective when? — targeting the binding-now forcing function R1 missed
3. Who benefits on the independent-pharmacy side, and is there a listed expression? — targeting the beneficiary gap

Round 3 (resolve remaining uncertainty):

1. How exactly do PBM-affiliated GPOs let pass-through promises coexist with retained value? — targeting the "what replaces the spread" mechanism
2. Does the CAA 2026 close the GPO route, in which markets, effective when? — targeting the hedge's shelf life
3. What is the live divestiture/breakup risk? — targeting the tail

Anchor source (Grokipedia, fetched before round 1; not counted against URL budget):

• Pharmacy benefit management — 91,111 chars — supplied the structural baseline (Big 3 ≈80% of US scripts, ~270M covered lives, 1,200+ independent closures since 2013) and the vocabulary for the spread/rebate distinction.

URLs fetched (11 successful, 6 failed):

Round 1:

• Drug Wholesalers and Brand-Name Drug Prices (Drug Channels) — industry analyst — the 94%/98%/96%-of-WAC margin arithmetic; CVS = ~31% of McKesson's US distribution.
• What CVS Pharmacy's New Cost-Plus Reimbursement Approach Means (Drug Channels) — industry analyst — "PBM profits relocate rather than disappear"; Cordavis benchmark route.
• The Future of Buy-and-Bill Market Access (Drug Channels) — industry analyst — the $16B MSO pivot; counter-evidence to Chain B.
• CVS Becomes Latest PBM to Overhaul Drug Pricing Formula (PharmExec) — trade press — the ClearNetwork/CostVantage/TrueCost sequence; the Gottlieb pre-emption quote.
• [Failed: https://www.fiercehealthcare.com/payer/cvs-caremark-launches-guaranteed-pbm-model-100-pass-through-pricing] — HTTP 403. New persistent-failure candidate.
• [Failed: https://www.bipc.com/when-pass-through-isn't-pass-through-pbm-gpos-and-the-reengineering-of-rebates] — HTTP 403. Content recovered via search snippet only; cited as such.

Round 2:

• Court dismisses PBMs' lawsuit against FTC (Healthcare Dive) — trade press — 8th Cir. dismissal 2026-07-01; Optum accepted proposed settlement June 2026.
• 2026 State PBM Reform Updates (Frier Levitt) — law firm — the full state NADAC-floor table; Arkansas HB 1150 injunction.
• Expansive reimbursement legislation on the move in New Jersey (NCPA) — trade association (interested party) — NJ A. 1502 detail.
• [Failed: https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark...] — HTTP 403. Notable: ftc.gov is federal primary and not currently in SOURCE_RELIABILITY.md.
• [Failed: https://www.ftc.gov/legal-library/browse/cases-proceedings/221-0114-caremark-rx-zinc-health-services-et-al-matter-insulin] — HTTP 403.
• [Failed: https://www.ajmc.com/view/ftc-reaches-settlement-with-cvs-caremark-to-curb-insulin-rebate-practices-cut-patient-costs] — HTTP 403.
• [Failed: https://www.healthcarefinancenews.com/news/ftc-announces-settlement-caremark-resolving-pbm-lawsuit] — HTTP 403.

Round 3:

• Ascent, Zinc, and Emisar (Grokipedia) — encyclopedic — 14,334 chars — GPO ownership/formation/jurisdiction; the $45M Illinois AG recovery.
• Five (or Maybe Six?) Reasons the Largest PBMs Operate GPOs (Drug Channels) — industry analyst — the load-bearing source: the explicit "no parallel effort to alter GPO safe harbor rules" regulatory-hedge reasoning; 3–5% of WAC admin fees.
• Congress Passes Landmark PBM Reform in 2026 Spending Bill (Mintz) — law firm — CAA 2026 market scope + 2028/2029 effective dates + BFSF definition + the affiliated-GPO ambiguity.
• Potential Big Impact If Firms That Own PBMs Must Break Up (Forbes) — news/opinion — the 2012→2023 revenue-mix migration; Patients Before Monopolies Act.

Search-layer-only claims (surfaced via WebSearch synthesis where the underlying page 403'd or was not fetched; weaker provenance, flagged inline above): the CVS ">75% of commercial lives" adoption figure; the $7.6B/2022 GPO fee estimate; the Express Scripts Feb-2026 / $7B / Ascent-reshoring claims; the Caremark $8.5B savings figure; the OptumRx "Cost Clarity" model name and 2028 target; NCPA's "thousands of closures in 2024-2025."

Tools used: WebSearch, WebFetch, _lib/grokipedia.py (grokipedia-fetch helper). Generated: 2026-07-17 09:30 America/Los_Angeles